These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 3513777

  • 1. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 1st communication: Effects on cardiovascular, visceral and renal functions and on blood.
    Matsuno Y, Taira N, Fujitani B, Ito T, Kadokawa T.
    Arzneimittelforschung; 1986; 36(1):55-62. PubMed ID: 3513777
    [Abstract] [Full Text] [Related]

  • 2. General pharmacology of the novel antiepileptic compound zonisamide. 2nd communication: effects on cardiovascular, visceral, renal and blood functions.
    Nakatsuji K, Matsuno Y, Nakamura N, Fujitani B, Ito T, Kadokawa T.
    Arzneimittelforschung; 1987 Oct; 37(10):1131-6. PubMed ID: 3435584
    [Abstract] [Full Text] [Related]

  • 3. General pharmacology of the novel angiotensin converting enzyme inhibitor alacepril. 2nd communication: Effects on central nervous and sensory systems and on the other functions.
    Matsuno Y, Hori H, Oka M, Nakamura H, Ito T, Kadokawa T.
    Arzneimittelforschung; 1986 Oct; 36(1):62-8. PubMed ID: 3513778
    [Abstract] [Full Text] [Related]

  • 4. General pharmacology of the new antimuscarinic compound vamicamide.
    Yamamoto T, Honbo T, Tokoro K, Kojimoto Y, Kodama R, Ohtsuka M, Shimomura K.
    Arzneimittelforschung; 1995 Dec; 45(12):1274-84. PubMed ID: 8595084
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. General pharmacological profile of the new cognition-enhancing agent nefiracetam.
    Kitano Y, Makino M, Usui C, Takasuna K, Kasai Y, Hirohashi M, Tamura K, Takayama S, Kojima H, Iizuka H.
    Arzneimittelforschung; 1994 Feb; 44(2A):199-210. PubMed ID: 8018090
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. General pharmacological properties of the new vasodilator flosequinan.
    Ikezono K, Fujita S, Umezato M, Hosoki E, Toba Y, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct; 42(10):1200-11. PubMed ID: 1472141
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antihypertensive activity of alacepril, an orally active angiotensin converting enzyme inhibitor, in renal hypertensive rats and dogs.
    Takeyama K, Minato H, Fukuya F, Kawahara S, Hosoki K, Kadokawa T.
    Arzneimittelforschung; 1985 Oct; 35(10):1502-7. PubMed ID: 3000389
    [Abstract] [Full Text] [Related]

  • 13. Tissue levels, tissue angiotensin converting enzyme inhibition and antihypertensive effect of the novel antihypertensive agent alacepril in renal hypertensive rats.
    Nambu K, Matsumoto K, Takeyama K, Hosoki K, Miyazaki H, Hashimoto M.
    Arzneimittelforschung; 1986 Oct; 36(1):47-51. PubMed ID: 3006710
    [Abstract] [Full Text] [Related]

  • 14. General pharmacological properties of the main metabolite of flosequinan.
    Fujita S, Ikezono K, Umezato M, Hosoki E, Toba Y, Ishikawa M, Kusunoki A, Shintani S.
    Arzneimittelforschung; 1992 Oct; 42(10):1212-22. PubMed ID: 1335257
    [Abstract] [Full Text] [Related]

  • 15. Effects of brotizolam on cardiovascular functions and autonomic nervous system.
    Kushiku K, Morishita H, Furukawa T, Kitagawa H, Ueno K, Kitagawa H, Kohei H.
    Arzneimittelforschung; 1986 Mar; 36(3A):552-9. PubMed ID: 3718577
    [Abstract] [Full Text] [Related]

  • 16. Antihypertensive activity of alacepril in spontaneously hypertensive rats and deoxycorticosterone acetate-salt hypertensive rats and dogs.
    Takeyama K, Minato H, Fukuya F, Kawahara S, Hosoki K, Kadokawa T.
    Arzneimittelforschung; 1985 Mar; 35(10):1507-12. PubMed ID: 3000390
    [Abstract] [Full Text] [Related]

  • 17. General pharmacological properties of the human corticotropin-releasing hormone corticorelin (human).
    Andoh K, Kimura T, Saeki I, Tabata R, Yamazaki S, Eguchi I, Hanazuka M, Horii D, Munt PL, Davis AS.
    Arzneimittelforschung; 1994 Jun; 44(6):715-26. PubMed ID: 8053970
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.
    Laubie M, Schiavi P, Vincent M, Schmitt H.
    J Cardiovasc Pharmacol; 1984 Jun; 6(6):1076-82. PubMed ID: 6084763
    [Abstract] [Full Text] [Related]

  • 19. General pharmacological properties of the potent angiotensin converting enzyme inhibitor rentiapril.
    Yamauchi H, Nishimura K, Nakata K, Suda H, Iso T, Shimizu M, Hiramatsu Y.
    Arzneimittelforschung; 1987 Feb; 37(2):157-64. PubMed ID: 3034298
    [Abstract] [Full Text] [Related]

  • 20. General pharmacological profile of the novel cholecystokinin-A antagonist loxiglumide.
    Saito T, Ukai K, Masuda T, Nakagawa T, Kimura K, Fujii M, Wakatsuki K, Saeki M, Kasai H.
    Arzneimittelforschung; 1997 Dec; 47(12):1375-82. PubMed ID: 9450167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.